Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

DISEASE CHARACTERISTICS: Histologically proven hematologic malignancy of 1 of the following types: Chronic myelogenous leukemia (CML) in chronic, accelerated, or blast* phase Acute leukemia with high-risk features at diagnosis such as: Philadelphia chromosome-positive acute lymphocytic leukemia** Acute myeloid leukemia with high-risk cytogenetics such as inv (3), t(3;3) del(5q), -5, del(7q), -7, +8, +11, abnormal 12p, del(20q), -20, or complex abnormalities** Acute leukemia with failure after one course of induction chemotherapy Acute leukemia in first relapse* or second remission High-risk lymphoblastic lymphoma in first remission Non-Hodgkin's lymphoma, Hodgkin's disease, or other malignant lymphoproliferative disease after first remission, if an autologous transplantation is not indicated Myelodysplastic or myeloproliferative syndromes ineligible for Protocol FHCRC-179 NOTE: * For patients with acute leukemia in relapse or CML in blast crisis, the search for an unrelated donor begins only if: High probability that the patient's medical condition will remain stable for the 3 to 6-month period needed to find a donorAn attempt at remission induction has been undertaken Referring physician and patient accept possibility that search for donor will be canceled if patient's condition worsens NOTE: ** For newly diagnosed patients with high-risk acute leukemia, early referral is encouraged so that an unrelated donor search may begin immediately Availability of an unrelated donor with: 1 HLA-A or B non-cross-reactive group (non-CREG) mismatch (except in CML in chronic phase or myelodysplastic syndrome) OR 1 HLA-A or B CREG mismatch OR An HLA-A, B, and C match with an HLA-DRB1 or DQB1 mismatch (no double mismatch) if 1 of the above 2 donor types unavailable No more than 1 HLA-A, B, and C mismatch No availability of an HLA-identical sibling or haploidentical relative incompatible for 0 or 1 HLA-A or B locus of the nonshared haplotypes For patients with diagnosis other than CML in chronic phase, 1 HLA-DR locus-incompatible related donor has priority over an HLA compatible or class IA or B CREG locus antigen-incompatible unrelated donor No severe aplastic anemia No leukoencephalopathy PATIENT CHARACTERISTICS: Age: Under 51 Eligible for transplantation until age 52 if the donor is identified prior to patient's 51st birthday Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: No severe hepatic disease, including acute hepatitis Renal: Creatinine less than 2 times normal Cardiovascular: No cardiac insufficiency requiring treatment No symptomatic coronary artery disease Pulmonary: No severe hypoxemia (i.e., PO2 less than 70 mm Hg) with decreased DLCO (i.e., DLCO less than 70% predicted) OR No mild hypoxemia (i.e., PO2 less than 80 mm Hg) with severely decreased DLCO (i.e., DLCO less than 60% predicted) No pulmonary fibrosis Other: No other nonmalignant disease that would severely limit life expectancy HIV negative No contraindication to total body irradiation (TBI) Patients excluded from this study because of contraindication to TBI may be treated on protocol FHCRC-739 PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy greater than 3,000 cGy to whole brain At least 6 months since prior involved-field radiotherapy greater than 1,500 cGy to chest or abdomen Surgery: Not specified